49.94
+0.16(+0.32%)
Currency In USD
Address
614 McKinley Place N.E.
Minneapolis, MN 55413
United States of America
Phone
612 379 8854
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3100
First IPO Date
February 09, 1989
Name | Title | Pay | Year Born |
Mr. Kim Kelderman | Chief Executive Officer, President & Director | 1.06M | 1967 |
Mr. Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer | 430,768 | 1975 |
Dr. Matthew F. McManus M.D., MBA, Ph.D. | President of Diagnostics & Genomics | 659,007 | 1969 |
Mr. William A. Geist | President of Protein Sciences Segment | 709,942 | 1969 |
Mr. James T. Hippel CPA | Executive Vice President of Finance & Chief Financial Officer | 924,742 | 1971 |
Ms. Cheryl Bethune | Senior Vice President & Chief Human Resources Officer | 0 | N/A |
Mr. Gerry Andros | Vice President of Sales and Marketing | 0 | N/A |
Mr. Martin Wirtz | Senior Vice President of Strategy & Corporate Development | 0 | N/A |
Mr. David Clair C.F.A. | Vice President of Investor Relations & Corporate Development | 0 | N/A |
Dr. Gary J. Latham Ph.D. | Vice President & Chief Technology Officer | 0 | N/A |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.